Search results
Showing 226 to 240 of 530 results for physical activity
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
None. Source guidance details Comes from guidance Physical activity: walking and cycling Number PH41 Date issued
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.
areas? Source guidance details Comes from guidance Physical activity: walking and cycling Number PH41 Date issued
Alcohol-use disorders: diagnosis and management of physical complications (CG100)
This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.
This quality standard covers adults with rehabilitation needs as a result of critical illness that required level 2 or level 3 critical care. It describes high-quality care in priority areas for improvement.
View quality statements for QS158Show all sections
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .
planning? Source guidance details Comes from guidance Physical activity: walking and cycling Number PH41 Date issued
made the recommendation for research, see the rationale section on physical activity and diet and other modifiable risk factors. Full...
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
This quality standard covers assessing, diagnosing and managing chronic obstructive pulmonary disease (COPD). It describes high-quality care in priority areas for improvement.
View quality statements for QS10Show all sections
Sections for QS10
- Quality statements
- Quality statement 1: Diagnosis with spirometry
- Quality statement 2: Inhaler technique
- Quality statement 3: Assessment for long-term oxygen therapy
- Quality statement 4: Pulmonary rehabilitation for stable COPD and exercise limitation
- Quality statement 5: Pulmonary rehabilitation after an acute exacerbation
- Quality statement 6: Emergency oxygen during an exacerbation
- Quality statement 7: Non-invasive ventilation
This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.
View quality statements for QS9Show all sections
Sections for QS9
- Quality statements
- Quality statement 1: N-terminal pro-B-type natriuretic peptide measurement
- Quality statement 2: Specialist assessment
- Quality statement 3: Medication for newly diagnosed and pre-existing chronic heart failure with reduced ejection fraction
- Quality statement 4: Review after changes in medication
- Quality statement 5: Review of people with chronic heart failure
- Quality statement 6: Cardiac rehabilitation
- Update information